Erik Greb joined the staff of Neurology Reviews in January 2012. Since then, he has attended scientific conferences, conducted video interviews, and written about clinical research in multiple sclerosis, epilepsy, Parkinson's disease, Alzheimer's disease, stroke, and other neurologic disorders. In addition to news articles, Erik has written investigative stories about multiple sclerosis, headache, and epilepsy. He previously wrote about pharmaceutical manufacturing, drug formulation and delivery, quality assurance, and regulation for Pharmaceutical Technology.
News
Staying alert for patients with narcolepsy
The chronic neurologic disorder entails not only excessive sleepiness but also social and professional challenges.
News
Liquid embolism of AVM tied to high cure rate
“Endovascular treatment using Onyx is able to achieve, on its own, a very efficient cure rate with a low morbidity and mortality rate,”
News
Tirofiban does not improve outcomes of endovascular treatment in stroke
Median Modified Rankin Scale (mRS) score at 90 days was 3 in both patients who received tirofiban and those who received placebo.
News
Newly approved drug improves sleep onset in insomnia
The drug also was associated with improved daytime function.
News
Is outpatient care as safe as inpatient for TIA, minor stroke?
The safety of outpatient care can be improved by correct risk stratification, then triaging patients based on their risk profile.
News
FDA OKs new adult insomnia med
Whereas the overall results are very positive, the improvements in daytime functioning are especially “exciting.”
News
Diabetes tied to Parkinson’s risk, more rapid disease progression
Diabetes is associated with a higher risk for incident Parkinson’s disease and with worse motor symptoms, more rapid disease progression, new...
News
Stroke thrombectomy alone fails noninferiority to bridging tPA
The rate of good functional outcome was 57% for patients who underwent direct thrombectomy and 65% among patients who received IV thrombolysis...
News
Beloved psychiatrist dies at 102
“He was always thinking creatively; he was always thinking intellectually,” said Angela Hill, widow of Dr. Irwin Marcus. “That was, to me, the...
News
Rituximab more effective than other MS treatments?
The risk for a first relapse was 6 times higher in patients receiving interferon beta or glatiramer acetate, compared with those receiving...
News
Cortical lesions predict risk for secondary progressive MS
High numbers of cortical lesions at diagnosis are indicative of a more serious disease course.
News
ADHD med may reduce apathy in Alzheimer’s disease
Methylphenidate provides a “modest but potentially clinically significant benefit for patients and caregivers,” said Dr. Jacobo Mintzer and...
News
FDA okays new oral CGRP antagonist for migraine prevention
With this approval, neurologists will be able to choose from four monoclonal antibodies and two gepants for the preventive treatment of migraine...
News
Aspirin and heparin increase bleeding risk during EVT
New data show that aspirin and heparin, alone or in combination, double the risk for symptomatic intracranial hemorrhage when given during...
News
Tranexamic acid fails to prevent ICH growth: TRAIGE trial results
“Larger studies with more specified population are needed to further assess safety and efficacy of tranexamic acid in patients with ICH.”